3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
14
Gastro-enteropancreatic neuroendocrine tumor
4
Carcinoid Tumor
3
Serotonin Syndrome
1
Neuroendocrine Tumors in Lung
1
Neoplastic Cells, Circulating
1
Gastrointestinal Neoplasms
1
Flushing
1
Diarrhea
1
Carcinoma, Hepatocellular
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
Everolimus
6
Sunitinib
3
Specimen Handling
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Injections
2
recombinant interferon alpha 2b-like protein
1
pasireotide
1
motesanib diphosphate
1
lanreotide
1
ibrutinib
1
ganitumab
1
fludarabine phosphate
1
cabozantinib
1
batifiban
1
abemaciclib
1
X-Rays
1
Sorafenib
1
Phantoms, Imaging
1
PM 01183
1
Oxaliplatin
1
Leucovorin
1
Interleukin-13
1
Fluorouracil
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Cryotherapy
1
Biopsy
1
Bevacizumab
1
Acupuncture Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoma, Islet Cell
×
lanreotide
×
NET
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled